Lenvatinib
Based on 101 publication(s) in Google Scholar
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.75%
- CAS. Nr.: 417716-92-8
- Formel: C21H19ClN4O4
- Molecular Weight:426.85
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Therapy Drug Library
HY-L080
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Rare Diseases Drug Library
HY-L102
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cardiotoxic Compound Library
HY-L225
-
Posttranslational Modification Library
HY-L226
-
FDA Kinase Inhibitor Library
HY-L230
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Lenvatinib
More- Signal Transduct Target Ther. 2025 Aug 1;10(1):244. [Abstract]
- Nature. 2026 Jun;654(8117):261-271. [Abstract]
- Cancer Cell. 2026 Jun 4:S1535-6108(26)00252-7. [Abstract]
- Drug Resist Updat. 2023 Jul:69:100976. [Abstract]
- Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- J Extracell Vesicles. 2024 Jul;13(7):e12468. [Abstract]
- Adv Sci (Weinh). 2025 May 8:e2501730. [Abstract]
- Adv Sci (Weinh). 2024 Jul 9:e2402327. [Abstract]
- J Exp Clin Cancer Res. 2025 Jan 11;44(1):11. [Abstract]
- Mol Ther. 2023 Jun 7;31(6):1829-1845. [Abstract]
- Biomark Res. 2026 Jan 15;14(1):11. [Abstract]
- MedComm (2020). 2022 Aug 26;3(3):e168. [Abstract]
- Cell Rep Med. 2025 Jul 15;6(7):102208. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cancer Lett. 2026 Feb 9:643:218316. [Abstract]
- Int J Biol Sci. 2023 Apr 23;19(7):2270-2288. [Abstract]
- Adv Healthc Mater. 2024 Nov;13(29):e2401398. [Abstract]
- Cell Death Dis. 2024 Jul 5;15(7):484. [Abstract]
- Angiogenesis. 2025 Feb 3;28(2):13. [Abstract]
- Int J Biol Macromol. 2026 Jan:336:149150. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 1. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Phytomedicine. 2026 Jul 25:157:158328. [Abstract]
- Phytomedicine. 2025 May 10:143:156824. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155767. [Abstract]
- EMBO J. 2021 Jun 1;40(11):e106771. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 30;17(30):42893-42914. [Abstract]
- Apoptosis. 2024 May 14. [Abstract]
- NPJ Precis Oncol. 2025 Aug 16;9(1):289. [Abstract]
- Biodes Manuf. 17 July 2021.
- J Transl Med. 2023 Jan 9;21(1):9. [Abstract]
- J Transl Med. 2022 Mar 7;20(1):116. [Abstract]
- Biomed Pharmacother. 2022 Jan;145:112391. [Abstract]
- Oncogene. 2024 Oct;43(42):3108-3120. [Abstract]
- Cell Death Discov. 2026 Mar 28. [Abstract]
- J Anal Test. 2025 Sep 25.
- Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]
- J Med Chem. 2024 Jul 11;67(13):10743-10773. [Abstract]
- Int J Pharm X. 2025 Apr 24:9:100335. [Abstract]
- Ecotoxicol Environ Saf. 2024 Oct 15:285:117031. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Eur J Med Chem. 2025 Dec 6:303:118471. [Abstract]
- Transl Res. 2024 May 24:S1931-5244(24)00107-5. [Abstract]
- Biochem Pharmacol. 2025 Sep 26;242(Pt 3):117367. [Abstract]
- Biochem Pharmacol. 2025 Jun 6:239:117032. [Abstract]
- Mar Drugs. 2024 Sep 28;22(10):444. [Abstract]
- Int J Pharm. 2026 Jul 10:700:127029. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Liver Int. 2023 Jul;43(7):1577-1592. [Abstract]
- Int J Mol Sci. 2025 Apr 18;26(8):3829. [Abstract]
- Int J Mol Sci. 2022 Sep 14;23(18):10677. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2439-2460. [Abstract]
- Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
- Front Pharmacol. 2024 May 21:15:1394241. [Abstract]
- Int Immunopharmacol. 2025 Mar 26:150:114278. [Abstract]
- Cancer Biol Ther. 2025 Dec;26(1):2532217. [Abstract]
- Cancers (Basel). 2025 Sep 9;17(18):2950. [Abstract]
- Cancers (Basel). 2025 Aug 29;17(17):2846. [Abstract]
- Ann Hepatol. 2025 Jun 1:101932. [Abstract]
- Cancers (Basel). 2023 Oct 22;15(20):5097. [Abstract]
- Bioengineered. 2024 Dec;15(1):2296775. [Abstract]
- J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
- Sci Rep. 2022 Jun 15;12(1):9951. [Abstract]
- Cell Signal. 2026 Aug:144:112514. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cell Signal. 2025 Nov:135:112067. [Abstract]
- Acta Derm Venereol. 2025 Apr 28:105:adv40697. [Abstract]
- Cell Signal. 2023 Nov:111:110828. [Abstract]
- Mol Med Rep. 2025 Nov;32(5):301. [Abstract]
- Med Oncol. 2021 Mar 17;38(4):41. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Med Oncol. 2020 Mar 12;37(4):24. [Abstract]
- J Hepatocell Carcinoma. 2026 May 14:13:579244.
- Front Oncol. 2022 Sep 8:12:944537. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- Front Biosci (Landmark Ed). 2026 Mar 31;31(4):47715. [Abstract]
- Funct Integr Genomics. 2025 Nov 4;25(1):230. [Abstract]
- Front Biosci (Landmark Ed). 2024 Jan 19;29(1):35. [Abstract]
- Am J Cancer Res. 2023 Nov 15;13(11):5368-5381. [Abstract]
- J Cancer Res Clin Oncol. 2026 May 21.
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100. [Abstract]
- J Mol Neurosci. 2020 Sep;70(9):1437-1444. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- Fundam Clin Pharmacol. 2021 Oct;35(5):919-929. [Abstract]
- PeerJ. 2023 Jan 25:11:e14610. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):625-635. [Abstract]
- Lasers Surg Med. 2024 Dec;56(10):845-853. [Abstract]
- Acta Pharm. 2024 Sep 14;74(3):441-459. [Abstract]
- SSRN. 2026 May 20.
- Res Sq. 2026 Apr 13.
- bioRxiv. 2025 Dec 5.
- Res Sq. 2024 Nov 18.
- bioRxiv. 2023 Nov 17.
- Research Square Preprint. 2023 Aug 5.
- SSRN. 2023 Apr 24.
- Research Square Print. 2023 Jan 9th,
- J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
- Research Square Print. 2022 Aug.
- Research Square Print. 2022 May.
- Research Square Preprint. 2021 May.
Customer Validation & Images
-
IHC
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
VEGFR1 22 nM (IC50) |
VEGFR2 4 nM (IC50) |
VEGFR3 5.2 nM (IC50) |
FGFR1 46 nM (IC50) |
FGFR2 |
FGFR3 |
FGFR4 |
PDGFRα 51 nM (IC50) |
PDGFRβ 39 nM (IC50) |
c-Kit 100 nM (IC50) |
RET |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
12 μM
Compound: 3
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 38870832] |
| BaF3 | IC50 |
3.23 nM
Compound: Lenvatinib
|
Antiproliferative activity against VEGFR2-transformed mouse BaF3 cells assessed as inhibition of cell proliferation incubated for 3 days by MTT assay
Antiproliferative activity against VEGFR2-transformed mouse BaF3 cells assessed as inhibition of cell proliferation incubated for 3 days by MTT assay
|
[PMID: 37429211] |
| HBL-100 | GI50 |
10 μM
Compound: 3
|
Growth inhibition of human HBL-100 cells
Growth inhibition of human HBL-100 cells
|
[PMID: 38870832] |
| HCCLM3 | IC50 |
27.81 μM
Compound: Lenvatinib
|
Antitumor activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antitumor activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
|
[PMID: 38919032] |
| HeLa | GI50 |
4 μM
Compound: 3
|
Growth inhibition of human HeLa cells
Growth inhibition of human HeLa cells
|
[PMID: 38870832] |
| Hep 3B2 | IC50 |
696.2 nM
Compound: Lenvatinib
|
Antiproliferative activity against human Hep3B cells incubated for 72 hrs by Cell counting kit 8 method
Antiproliferative activity against human Hep3B cells incubated for 72 hrs by Cell counting kit 8 method
|
[PMID: 37335602] |
| Huh-7 | IC50 |
850.9 nM
Compound: Lenvatinib
|
Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by Cell counting kit 8 method
Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by Cell counting kit 8 method
|
[PMID: 37335602] |
| HUVEC | IC50 |
3 nM
Compound: E7080
|
Inhibition of VEGF-induced cell proliferation of HUVEC incubated for 72 hrs by by CCK8 assay
Inhibition of VEGF-induced cell proliferation of HUVEC incubated for 72 hrs by by CCK8 assay
|
[PMID: 31096155] |
| HUVEC | IC50 |
3.47 nM
Compound: Lenvatinib
|
Antiproliferative activity against VEGF-stimulated HUVEC assessed as inhibition of cell proliferation incubated for 3 days by MTT assay
Antiproliferative activity against VEGF-stimulated HUVEC assessed as inhibition of cell proliferation incubated for 3 days by MTT assay
|
[PMID: 37429211] |
| MHCC97H | IC50 |
>80 μM
Compound: Lenvatinib
|
Antitumor activity against human MHCC97H cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antitumor activity against human MHCC97H cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
|
[PMID: 38919032] |
| SW1573 | GI50 |
8 μM
Compound: 3
|
Growth inhibition of human SW1573 cells
Growth inhibition of human SW1573 cells
|
[PMID: 38870832] |
| T47D | GI50 |
10 μM
Compound: 3
|
Growth inhibition of human T47D cells
Growth inhibition of human T47D cells
|
[PMID: 38870832] |
| WiDr | GI50 |
19 μM
Compound: 3
|
Growth inhibition of human WiDr cells
Growth inhibition of human WiDr cells
|
[PMID: 38870832] |
Lenvatinib (E7080) has IC50s of 4, 5.2, 22 nM for VEGFR2 (KDR), VEGFR3 (Flt-4), and VEGFR1 (Flt-1), respectively. Lenvatinib inhibits PDGFRα, PDGFRβ, FGFR1, and KIT with IC50s of 51, 39, 46, and 100 nM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Lenvatinib (E7080) inhibits the growth of H146 tumor at 30 and 100 mg/kg (BID, QDx21) in a dose-dependent manner and causes tumor regression at 100 mg/kg in H146 xenograft model. IHC analysis with anti-CD31 antibody shows that lenvatinib at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and STI571 treatment[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 417716-92-8
-
Appearance Solid
-
Molecular Weight 426.85
-
Formel C21H19ClN4O4
-
Color Off-white to light yellow
-
SMILES
O=C(N)C1=C(C=C2N=CC=C(C2=C1)OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)OC
-
Synonyms
E7080
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (101)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. [Abstract]2025 Aug 1;10(1):244. PMID: 40750772 -
Nature
2026 Jun;654(8117):261-271. PMID: 41986722 -
Cancer Cell
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. [Abstract]2026 Jun 4:S1535-6108(26)00252-7. PMID: 42242232 -
Drug Resist Updat
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. [Abstract]2023 Jul:69:100976. PMID: 37210811 -
Nat Commun
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]2025 Nov 18;16(1):10096. PMID: 41253833 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
J Extracell Vesicles
Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma. [Abstract]2024 Jul;13(7):e12468. PMID: 38944674 -
Adv Sci (Weinh)
PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. [Abstract]2025 May 8:e2501730. PMID: 40344394 -
Adv Sci (Weinh)
Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. [Abstract]2024 Jul 9:e2402327. PMID: 38981014 -
J Exp Clin Cancer Res
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. [Abstract]2025 Jan 11;44(1):11. PMID: 39794830 -
Mol Ther
miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism. [Abstract]2023 Jun 7;31(6):1829-1845. PMID: 37143325 -
Biomark Res
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC. [Abstract]2026 Jan 15;14(1):11. PMID: 41540504 -
MedComm (2020)
Interferon regulatory factor 1-triggered free ubiquitin protects the intestines against radiation-induced injury via CXCR4/FGF2 signaling. [Abstract]2022 Aug 26;3(3):e168. PMID: 36051984 -
Cell Rep Med
CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2025 Jul 15;6(7):102208. PMID: 40592346 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cancer Lett
The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma. [Abstract]2026 Feb 9:643:218316. PMID: 41672222 -
Int J Biol Sci
Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma. [Abstract]2023 Apr 23;19(7):2270-2288. PMID: 37151886 -
Adv Healthc Mater
A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells. [Abstract]2024 Nov;13(29):e2401398. PMID: 39359011 -
Cell Death Dis
BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC. [Abstract]2024 Jul 5;15(7):484. PMID: 38969639 -
Angiogenesis
Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. [Abstract]2025 Feb 3;28(2):13. PMID: 39899169 -
Int J Biol Macromol
Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2026 Jan:336:149150. PMID: 41274476 -
Acta Pharmacol Sin
LAMTOR5 promotes hepatoma growth in mice by disrupting LC3-p62-mediated autophagy and preventing p62 proteasome degradation. [Abstract]2026 Jan 1. PMID: 41478881 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Phytomedicine
Antitumor and resensitizing effects of wogonin in thyroid cancer via PDGFRB-dependent mechanisms. [Abstract]2026 Jul 25:157:158328. PMID: 42217345 -
Phytomedicine
Ponicidin promotes ferroptosis to enhance treatment sensitivity in Lenvatinib-resistant hepatocellular carcinoma cells through regulation of KEAP1/NRF2. [Abstract]2025 May 10:143:156824. PMID: 40382941 -
Phytomedicine
Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma. [Abstract]2024 Jul 25:130:155767. PMID: 38833789 -
EMBO J
Inhibition of Syk promotes chemical reprogramming of fibroblasts via metabolic rewiring and H2 S production. [Abstract]2021 Jun 1;40(11):e106771. PMID: 33909912 -
ACS Appl Mater Interfaces
Methacrylated Carrageenan/Gelatin Interpenetrating Network Microspheres Loaded with Targeted Drugs and combined with PD-L1 Inhibitors for Hepatocellular Carcinoma Treatment. [Abstract]2025 Jul 30;17(30):42893-42914. PMID: 40671639 -
Apoptosis
EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis. [Abstract]2024 May 14. PMID: 38743191 -
NPJ Precis Oncol
Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma. [Abstract]2025 Aug 16;9(1):289. PMID: 40819143 -
-
J Transl Med
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]2023 Jan 9;21(1):9. PMID: 36624452 -
J Transl Med
Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. [Abstract]2022 Mar 7;20(1):116. PMID: 35255940
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Mar 7;20(1):116. [Abstract]
H&E examination of vehicle and Lenvatinib (10 mg/kg daily by oral gavage)-treated tumors revealed markedly increase tumor necrosis and desmoplasia in the Lenvatinib-treated samples.
-
Biomed Pharmacother
The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib. [Abstract]2022 Jan;145:112391. PMID: 34847475 -
Oncogene
GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma. [Abstract]2024 Oct;43(42):3108-3120. PMID: 39251847 -
Cell Death Discov
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. [Abstract]2026 Mar 28. PMID: 41896541 -
-
Cell Death Discov
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. [Abstract]2021 Nov 18;7(1):359. PMID: 34795217
Lenvatinib purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]
Lenvatinib (1000 nM) has demonstrated the ability to significantly inhibit cell proliferation, and knockout of NF1 and DUSP9 significantly blocks the ability of lenvatinib to inhibit cell proliferation as well as the effect on cell number.
-
J Med Chem
Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. [Abstract]2024 Jul 11;67(13):10743-10773. PMID: 38919032 -
Int J Pharm X
An aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma. [Abstract]2025 Apr 24:9:100335. PMID: 40927752 -
Ecotoxicol Environ Saf
Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway. [Abstract]2024 Oct 15:285:117031. PMID: 39341137 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Eur J Med Chem
Discovery of novel small molecule inhibitor targeting the tumor promoting effect of transcription factor PLAGL2. [Abstract]2025 Dec 6:303:118471. PMID: 41365089 -
Transl Res
2024 May 24:S1931-5244(24)00107-5. PMID: 38797432 -
Biochem Pharmacol
Dual activation of PPARα/γ by bezafibrate triggers PINK1/Parkin-Mediated mitophagy to enhance lenvatinib sensitivity in hepatocellular carcinoma. [Abstract]2025 Sep 26;242(Pt 3):117367. PMID: 41016578 -
Biochem Pharmacol
Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma. [Abstract]2025 Jun 6:239:117032. PMID: 40482839 -
Mar Drugs
New Fusarochromanone Derivatives from the Marine Fungus Fusarium equiseti UBOCC-A-117302. [Abstract]2024 Sep 28;22(10):444. PMID: 39452852 -
Int J Pharm
cR10-modified liposomes for efficient topical delivery of lenvatinib to the posterior segment: Enhanced suppression of choroidal neovascularization. [Abstract]2026 Jul 10:700:127029. PMID: 42225176 -
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Liver Int
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway. [Abstract]2023 Jul;43(7):1577-1592. PMID: 37208925 -
Int J Mol Sci
Myristoyl-CM4 Exhibits Direct Anticancer Activity and Immune Modulation in Hepatocellular Carcinoma: Evidence from In Vitro and Mouse Model Studies. [Abstract]2025 Apr 18;26(8):3829. PMID: 40332513 -
Int J Mol Sci
Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. [Abstract]2022 Sep 14;23(18):10677. PMID: 36142591 -
Cell Oncol (Dordr)
GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. [Abstract]2024 Dec;47(6):2439-2460. PMID: 39718738 -
Cell Oncol (Dordr)
Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. [Abstract]2025 Apr;48(2):487-504. PMID: 39585643 -
Front Pharmacol
Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. [Abstract]2024 May 21:15:1394241. PMID: 38835670 -
Int Immunopharmacol
Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma. [Abstract]2025 Mar 26:150:114278. PMID: 39954659 -
Cancer Biol Ther
Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation. [Abstract]2025 Dec;26(1):2532217. PMID: 40653759 -
Cancers (Basel)
Cabozantinib Sensitizes NSCLC Cells to Radiation by Inducing Ferroptosis via STAT3/MCL1/BECN1/SLC7A11 Axis Suppression. [Abstract]2025 Sep 9;17(18):2950. PMID: 41008795 -
Cancers (Basel)
ITGA2 Mediates the Resistance of Hepatocellular Carcinoma to Lenvatinib by Activating the AKT/FOXO3A Signaling Pathway. [Abstract]2025 Aug 29;17(17):2846. PMID: 40940943 -
Ann Hepatol
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma. [Abstract]2025 Jun 1:101932. PMID: 40460973 -
Cancers (Basel)
Dose Consideration of Lenvatinib's Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. [Abstract]2023 Oct 22;15(20):5097. PMID: 37894463 -
Bioengineered
Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line. [Abstract]2024 Dec;15(1):2296775. PMID: 38184822 -
J Cell Mol Med
Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. [Abstract]2021 Jan;25(1):549-560. PMID: 33210432
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The cell viability is measured by CCK-8 assay at different time intervals (24, 48, 72 and 96 h) when cells are cultured with 5 μM Lenvatinib.
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The mRNA expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. VEGFR2 mRNA expression is up-regulated in HepG2-LR and Huh7LR cells.
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The protein expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. Western blotting results show the downstream target RAS/MEK/ERK axis of VEGFR2 are obviously up‐regulated in HepG2-LR and Huh7-LR cells compared with their parental cells.
-
Sci Rep
Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. [Abstract]2022 Jun 15;12(1):9951. PMID: 35705678 -
Cell Signal
A novel diagnostic and prognostic biomarker FSD1L facilitates EMT and Lenvatinib resistance via the WNT/β-catenin pathway in hepatocellular carcinoma. [Abstract]2026 Aug:144:112514. PMID: 41935591 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cell Signal
Melatonin reverses lenvatinib resistance in HCC by regulating the ATF4-NRF1 pathway mediated by ceramide synthase 6. [Abstract]2025 Nov:135:112067. PMID: 40818539 -
Acta Derm Venereol
Possible Clinical Effects of Ketoconazole on Sorafenib-induced Hand-Foot Skin Reaction and Cytoprotection Mechanisms of Antifungal Agents against Multikinase Inhibitor-induced Keratinocyte Toxicity. [Abstract]2025 Apr 28:105:adv40697. PMID: 40289816 -
Cell Signal
2023 Nov:111:110828. PMID: 37517671 -
Mol Med Rep
Aberrant activation of the PI3K/AKT/HIF‑1α pathway promotes glycolysis and lenvatinib resistance in liver cancer. [Abstract]2025 Nov;32(5):301. PMID: 40878941 -
Med Oncol
Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. [Abstract]2021 Mar 17;38(4):41. PMID: 33730237 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Med Oncol
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. [Abstract]2020 Mar 12;37(4):24. PMID: 32166604 -
-
Front Oncol
Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. [Abstract]2022 Sep 8:12:944537. PMID: 36158676 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
Front Biosci (Landmark Ed)
2026 Mar 31;31(4):47715. PMID: 42052849 -
Funct Integr Genomics
DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway. [Abstract]2025 Nov 4;25(1):230. PMID: 41186842 -
Front Biosci (Landmark Ed)
Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway. [Abstract]2024 Jan 19;29(1):35. PMID: 38287824 -
Am J Cancer Res
Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy. [Abstract]2023 Nov 15;13(11):5368-5381. PMID: 38058824 -
-
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]2024 Apr 15:1237:124100. PMID: 38547701 -
J Mol Neurosci
Deferoxamine Ameliorates Compressed Spinal Cord Injury by Promoting Neovascularization in Rats. [Abstract]2020 Sep;70(9):1437-1444. PMID: 32383023 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
Fundam Clin Pharmacol
2021 Oct;35(5):919-929. PMID: 33523504 -
PeerJ
Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. [Abstract]2023 Jan 25:11:e14610. PMID: 36718449 -
Eur J Drug Metab Pharmacokinet
Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors. [Abstract]2021 Sep;46(5):625-635. PMID: 34275128 -
Lasers Surg Med
Study on the Synergistic Mechanism of Photodynamic Therapy Combined With Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma. [Abstract]2024 Dec;56(10):845-853. PMID: 39468974 -
Acta Pharm
The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver. [Abstract]2024 Sep 14;74(3):441-459. PMID: 39279523 -
-
-
-
-
-
-
-
-
J Oncol
Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. [Abstract]2022 Oct 18;2022:4537343. PMID: 36304988
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
HepG2 and HepG2/R cells are treated with indicated doses of Lenvatinib for 24 h, and cellular viabilities are measured.
Lenvatinib purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
HepG2 and HepG2/R cells are treated with or without Lenvatinib (20 μM) for 24 h, and indicated proteins are measured by western blots.
-
-
-
Lösungsmittel & Löslichkeit
DMSO : 12.5 mg/mL (29.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% Methylcellulose/saline water
Solubility: 6.67 mg/mL (15.63 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
H146 (1.2×103 cells/50 μL/well) in SFM containing 0.5% BSA are cultured in 96-well multi-plates. After overnight culture at 37°C, SFM (150 μL/well) containing 0.5% FBS and several concentrations of SCF are added with or without several concentrations of compound. After culture for 72 hr, the ratios of surviving cells are measured by WST-1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Female BALB/c nude mice (8-12 weeks old, 20-25 g) are maintained under clean-room conditions. H146 tumor cells (6.5×106) are implanted subcutaneously (s.c.) into the flank region of mice. Twelve days after inoculation, mice are randomized into control (n=12) and treatment (n=6 or n=5) groups and this point in time is identified as day 1. Lenvatinib and STI571, and VEGF neutralization antibody are suspended in 0.5% methylcellulose and saline, respectively, and administered orally twice a day for lenvatinib and STI571 and twice a week for antibody from day 1 to day 21. Tumor volume is measured on the indicated days and calculated. Antitumor activity is shown as a relative tumor volume (RTV=calculated tumor volume at indicated days/volume on day 1).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kudo M, et al. Lenvatinib versus Bay 43-9006 in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. [Content Brief]
[2]. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. [Content Brief]
[3]. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671. [Content Brief]
[4]. Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3427 mL | 11.7137 mL | 23.4274 mL | 58.5686 mL |
| 5 mM | 0.4685 mL | 2.3427 mL | 4.6855 mL | 11.7137 mL | |
| 10 mM | 0.2343 mL | 1.1714 mL | 2.3427 mL | 5.8569 mL | |
| 15 mM | 0.1562 mL | 0.7809 mL | 1.5618 mL | 3.9046 mL | |
| 20 mM | 0.1171 mL | 0.5857 mL | 1.1714 mL | 2.9284 mL | |
| 25 mM | 0.0937 mL | 0.4685 mL | 0.9371 mL | 2.3427 mL |
Lenvatinib Related Classifications
HY-10981 Related Classifications
Powered by Bioz